Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection
Status:
Active, not recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if the use of Envarsus in place of
Tacrolimus-immediate release (IR) in rapid metabolizers post kidney transplant will reduce
incidence of BK infection. Efficacy evaluations will include measurement of urine and serum
BK values at specified time points and review of any biopsy for BK virus nephropathy.
Incidence of rejection, graft failure, and graft dysfunction will also be measured at
specified time points.